A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection.
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2012
At a glance
- Drugs GS 6620 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 22 Apr 2012 Results presented at the 47th Annual Meeting of the European Association for the Study of the Liver.
- 13 Jan 2012 Actual end date Jan 2012 added as reported by ClinicalTrials.gov.
- 13 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History